Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
J Pediatr ; 164(3): 529-35.e1-4, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24359940

ABSTRACT

OBJECTIVES: To describe the clinical manifestations and short-term outcomes of adenoviral infections in neonates and review all published cases to better determine impact and treatment outcomes. STUDY DESIGN: Retrospective cohort study of all neonates hospitalized at Children's Medical Center (CMC) and Parkland Memorial Hospital (PMH), Dallas, TX with laboratory-confirmed adenoviral infection from January 1,1995-December 31, 2012. Neonates were identified by review of the CMC Virology Laboratory's prospective database of all positive adenovirus tests performed in the inpatient and ambulatory settings, and at PMH, of a prospective neonatal database that included all neonatal intensive care unit admissions. Patients also were identified by discharge International Classification of Disease, 9th edition codes for adenoviral infection. The medical records were reviewed, and a review of the English literature was performed. RESULTS: During 17 years, 26 neonates had adenoviral infection (25, CMC; 1, PMH). The principle reasons for hospitalization were respiratory signs (88%) and temperature instability (65%). Five (19%) had disseminated disease and 4 (80%) of these infants died. Ribavirin or cidofovir treatment, as well as immune globulin intravenous, did not improve outcomes except in 1 neonate. Literature review (n = 72) combined with our data found that disseminated infection was associated with death (68% vs 21% with localized infection, P < .001). In addition, neonates <14 days of age were more likely to have disseminated disease (44% vs 12%, P = .004) and death (48% vs 8%; P < .001). CONCLUSION: Adenoviral infection in hospitalized neonates was associated with severe morbidity and mortality, especially when infection was disseminated and involved the respiratory tract. Development of new therapeutic strategies is needed.


Subject(s)
Adenoviridae Infections/epidemiology , Adenoviridae/genetics , Adenoviridae Infections/drug therapy , Age Factors , Antiviral Agents/therapeutic use , Body Temperature , Cidofovir , Cohort Studies , Cough/virology , Cytosine/analogs & derivatives , Cytosine/therapeutic use , Diarrhea/virology , Fatigue/virology , Female , Gastrointestinal Hemorrhage/virology , Hepatomegaly/virology , Humans , Hypotension/virology , Hypoxia/virology , Immunoglobulins, Intravenous/therapeutic use , Infant, Newborn , Intensive Care Units, Neonatal , Irritable Mood , Male , Muscle Hypotonia/virology , Organophosphonates/therapeutic use , Pancytopenia/virology , Polymerase Chain Reaction , Respiratory Sounds , Retrospective Studies , Ribavirin/therapeutic use , Splenomegaly/virology , Tachypnea/virology , Vomiting/virology
SELECTION OF CITATIONS
SEARCH DETAIL